Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon TLR7/8 Agonist With or Without Pembrolizumab in Advanced or Metastatic Solid Tumors
2024-517150-10-00Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label trial of ACP-017 in Non-hematologic malignancy, head and neck squamous cell carcinoma (HNSCC), anal cancer and 6 more (2 arms), sponsored by Ascendis Pharma. Primary endpoints: Incidence and severity of serious adverse events and adverse events, Incidence of dose limiting toxicities (DLTs) and 1 more. Started Oct 2024; status: completed.
02
Drugs
ACP-017
03
Conditions
Non-hematologic malignancyhead and neck squamous cell carcinoma (HNSCC)anal cancerVulval carcinomaCervical Cancer (CC)
Beyond the preview
Go deeper on 2024-517150-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517150-10-00.